KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $116.4 million.

  • CRISPR Therapeutics AG's Cash from Financing Activities rose 58981.99% to $116.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $426.0 million, marking a year-over-year increase of 2832.73%. This contributed to the annual value of $426.0 million for FY2025, which is 2832.73% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Cash from Financing Activities stood at $116.4 million for Q4 2025, which was up 58981.99% from $296.8 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Cash from Financing Activities peaked at $305.9 million during Q1 2024, and registered a low of -$466000.0 during Q2 2024.
  • Its 5-year average for Cash from Financing Activities is $55.5 million, with a median of $10.5 million in 2022.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Cash from Financing Activities surged by 1986386.93% in 2021, and later tumbled by 10277.96% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Cash from Financing Activities stood at $6.3 million in 2021, then plummeted by 60.66% to $2.5 million in 2022, then surged by 1471.39% to $38.9 million in 2023, then plummeted by 56.66% to $16.9 million in 2024, then surged by 589.82% to $116.4 million in 2025.
  • Its Cash from Financing Activities was $116.4 million in Q4 2025, compared to $296.8 million in Q3 2025 and $2.3 million in Q2 2025.